Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Cancer Biol Ther. 2024 Dec 31;25(1):2331273. doi: 10.1080/15384047.2024.2331273. Epub 2024 Mar 27.
To investigate the influence of pretreatment neutrophil-to-lymphocyte ratio (NLR) and procalcitonin (PCT) on progression-free survival (PFS) in extensive-stage small-cell lung cancer (SCLC) patients.
A total of 100 extensive-stage SCLC patients were enrolled in our study. Patients were stratified according to the median values of pretreatment NLR and PCT levels: low NLR group (NLR ≤3.17), high NLR group (NLR＞3.17), low PCT group (PCT ≤0.06; ng/ml), high PCT group (PCT＞0.06; ng/ml). The Kaplan-Meier method and multivariable Cox regression model were used to reveal the prognostic effects of pretreatment NLR and PCT on PFS.
The median PFS of the total extensive-stage SCLC patients was 6.0 months. The median PFS of low pretreatment NLR group (NLR ≤3.17) was not significantly different from that of high pretreatment NLR group (6.2 months vs 5.8 months; = .675). Patients with low pretreatment PCT (PCT ≤0.06; ng/ml) had significantly better PFS than patients with high pretreatment PCT (PCT＞0.06; ng/ml) (6.9 months vs 5.7 months; = .043). With the multivariable Cox regression analysis, the response to first-line chemotherapy ( ≤ .001) and pretreatment PCT (HR = 0.516; 95%CI 0.326-0.817; = .005) were identified as independent factors associated with PFS.
Pretreatment PCT is an independent factor associated with PFS in extensive-stage SCLC patients treated with first-line chemotherapy, but pretreatment NLR reflects no significant prognostic value in our study.
本研究旨在探讨广泛期小细胞肺癌（SCLC）患者治疗前中性粒细胞与淋巴细胞比值（NLR）和降钙素原（PCT）对无进展生存期（PFS）的影响。
本研究共纳入 100 例广泛期 SCLC 患者。根据治疗前 NLR 和 PCT 水平的中位数将患者分为低 NLR 组（NLR≤3.17）、高 NLR 组（NLR＞3.17）、低 PCT 组（PCT≤0.06ng/ml）和高 PCT 组（PCT＞0.06ng/ml）。采用 Kaplan-Meier 法和多变量 Cox 回归模型分析治疗前 NLR 和 PCT 对 PFS 的预后影响。
所有广泛期 SCLC 患者的中位 PFS 为 6.0 个月。低 NLR 组（NLR≤3.17）的中位 PFS 与高 NLR 组（6.2 个月比 5.8 个月； = .675）无显著差异。与高 NLR 组相比，低 PCT 组（PCT≤0.06ng/ml）患者的 PFS 显著更长（6.9 个月比 5.7 个月； = .043）。多变量 Cox 回归分析显示，一线化疗的疗效（ ≤ .001）和治疗前 PCT（HR = 0.516；95%CI 0.326-0.817； = .005）是与 PFS 相关的独立因素。
治疗前 PCT 是广泛期 SCLC 患者接受一线化疗后 PFS 的独立影响因素，而 NLR 在本研究中未显示出显著的预后价值。
